Femipro Official Website › Urinary health supplement guide
The Urinary Health Supplement Guide
Across the urinary supplement aisle, cranberry has the strongest evidence, probiotics have a null Cochrane review, D-mannose has a thin one and uva-ursi has a randomised trial that went the wrong way. The intervention with the best evidence of all is not a supplement: it is pelvic floor muscle training, and it is free.
Written for anyone deciding about this category, including somebody who ends up buying nothing.
What actually works, in order
Eight options, and the two with the best evidence are not products.
| Option | Evidence | Verdict |
|---|---|---|
| Pelvic floor muscle training | Cochrane review: women doing it were substantially more likely to report cure or improvement than untreated controls. ACP guideline first line for stress incontinence. | Best evidence of anything on this page, and free. Programmes run three months or more |
| Bladder training | ACP guideline first line for urgency incontinence. | Strong, and free. Requires a clinician's instruction to do properly |
| Cranberry | Cochrane review of 50 trials in 8,857 people: reduced symptomatic UTI overall and in women with recurrent infection. | The best-supported supplement in the aisle. No dose-response for proanthocyanidin content was demonstrable |
| Probiotics | Cochrane review of 9 trials in 735 people: no significant reduction in recurrent symptomatic UTI. | Formally null. A benefit cannot be ruled out but has not been shown |
| D-mannose | Widely sold, with a much thinner trial record than cranberry. | Unproven. Dosed in grams, so a small blend cannot carry a studied amount |
| Uva-ursi (bearberry) | REGATTA: higher symptom burden than an antibiotic and more pyelonephritis. ATAFUTI: no benefit. | Two unfavourable randomised trials. Short courses only |
| Berberine | Good meta-analysis, for blood lipids. Nothing comparable for the urinary tract. | Active, but studied for something else. Carries a real interaction profile |
| Mimosa pudica | No human trial for any urinary, bladder or vaginal outcome. | No human evidence. Traditional use only |
The two rows at the top cost nothing. That ordering is not a rhetorical device; it is what the evidence says, and it is on a page published by somebody who sells row three and rows four to eight.
If you take one thing from this guide, take the top two rows. The American College of Physicians recommends pelvic floor muscle training for stress incontinence, bladder training for urgency incontinence, and weight loss with exercise for women who are obese, before anything else. A supplement can sit alongside those. It is not a substitute for them, and anyone selling you one as a substitute is selling you something worse than what you could have for free.
Cranberry, in detail
A real effect, in a defined group, with three caveats the marketing skips.
Cranberry is the reason this aisle exists and it is the only item in it with a genuinely strong systematic review. The 2023 Cochrane review pooled 50 randomised trials across 8,857 participants and found cranberry products reduced symptomatic, culture-verified urinary tract infection, with a risk ratio of 0.70 overall and 0.74 in women with recurrent infection, at moderate certainty. A 2017 meta-analysis restricted to otherwise healthy women agreed. NCCIH puts the effect at around 25 percent in the groups where it works.
The mechanism is anti-adhesion rather than antibacterial. Proanthocyanidins interfere with E. coli attaching to the urinary tract lining, and a dose-ranging study in 32 volunteers showed that activity in urine is dose-dependent and persists up to 24 hours at 72 mg of proanthocyanidin a day.
Now the parts a sales page leaves out. The Cochrane review found little or no benefit in elderly institutionalised people, in pregnancy, or in people with bladder-emptying problems. And it found no demonstrable difference between low, moderate and high proanthocyanidin doses, which is awkward for the whole standardisation marketing angle and should make you suspicious of any product charging a premium for a higher percentage.
NCCIH is also explicit that cranberry is not a substitute for treating an infection that already exists. Prevention and treatment are different questions and only the first one has this evidence behind it.
Probiotics and the vaginal microbiome
Good biology, a null review, and a delivery route nobody mentions.
The biology is genuinely interesting. Ravel and colleagues profiled 396 women and found that most vaginal communities are dominated by a single lactobacillus species, producing lactic acid and holding the environment acidic. L. crispatus is one of those species. Since the urinary tract is adjacent, supporting that community looks like a sensible target.
The clinical evidence has not followed. The Cochrane review pooled nine trials in 735 people and found no significant reduction in recurrent symptomatic urinary infection, with most studies at high risk of bias. The best trial of L. crispatus specifically, a phase 2 study in 100 premenopausal women, found recurrence in 15 percent against 27 percent on placebo, which did not reach statistical significance. A more recent pooled analysis in premenopausal women reported a favourable direction, and it was published in a journal with minimal peer review and does not overturn the Cochrane result.
The one clearly positive randomised trial, Lactin-V in the New England Journal of Medicine, was for bacterial vaginosis rather than urinary infection.
Both positive L. crispatus trials delivered the organism intravaginally, as a suppository. Neither used an oral capsule. A swallowed capsule has to survive stomach acid, transit the gut, and then reach a different anatomical site entirely. That is not a minor difference in formulation; it is a different intervention, and no oral product should claim those results.
One more thing worth carrying into any purchase. NCCIH states plainly that probiotic effects are strain-specific: if one kind of lactobacillus helps with something, that does not mean another kind will. So a label naming its strains is doing better than one that does not. A label naming strains and printing no colony count for any of them has given you half of a useful disclosure.
Uva-ursi, berberine and the rest
One with unfavourable trials, one studied for something else, one with nothing.
Uva-ursi, or bearberry, is the ingredient most likely to be mis-sold in this category, because its traditional reputation is strong and its trial record is not. The REGATTA trial randomised 398 women against fosfomycin: uva-ursi reduced antibiotic courses, but it failed non-inferiority on symptom burden and produced more pyelonephritis, eight cases against two. ATAFUTI randomised 382 women and found no benefit on symptoms and no significant reduction in antibiotic use.
There is also a duration limit, and it comes from chemistry rather than from those trials. Arbutin is excreted in urine largely as hydroquinone, and one crossover study recovered about 65 percent of an oral dose that way. A published risk assessment concludes ordinary short-term doses stay within safe exposure limits; it was written by three employees of a bearberry product manufacturer, and it addresses short-term use only. Long continuous use has not been assessed by anyone.
Berberine is pharmacologically real and studied for the wrong thing. Its oral bioavailability is under one percent and yet it is active by mouth: the best meta-analysis of berberine trials is about blood lipids. There is no comparable synthesis for urinary outcomes. What does carry over regardless is the interaction profile, and it is the most important safety point in this whole guide.
Mimosa pudica appears on several labels in this aisle and has no human trial for any relevant outcome. The published record is an in vitro study from 1990 using leaf material, a study in experimentally infected chickens, and a review of the seed mucilage as a pharmaceutical excipient. The FTC requires that traditional-use claims are either backed by science or clearly qualified as not being. Take that as the standard when you read a label.
The interaction that matters most in this aisle
One ingredient, four drug classes, and two habits worth keeping.
Berberine inhibits CYP3A4 and P-glycoprotein, the machinery that clears a very long list of drugs. A human study found it raised ciclosporin exposure by 19 percent. A 2025 crossover trial found a dose-dependent interaction with metformin using a berberine-containing plant. Berberine also lowers blood glucose in its own right. The FDA warns that these combinations can be dangerous. Take the bottle to a pharmacy counter.
Two other safety habits for this aisle. First, no supplement in it is a treatment for an infection, and the danger of treating one as though it were is delay. Burning that worsens, fever, flank pain or blood in the urine needs a clinician the same day; MedlinePlus and NIDDK describe what is what.
Second, know which problem you have. The NOBLE survey found overactive bladder in 16.9 percent of US women and, contrary to the category's usual framing, 16.0 percent of men. Urge incontinence, stress incontinence and recurrent infection are three different things with three different first-line answers, and a capsule does not distinguish between them. A clinician does, in one appointment, and it changes what helps.
How the capsule we sell measures up
The guide, applied to the thing this website sells.
It would be strange to publish all of that and then not apply it. Femipro contains cranberry, which is the best-supported item in the aisle. It also contains uva-ursi, which has two unfavourable randomised trials; berberine, which is studied for something else and carries the interaction profile above; mimosa pudica, which has no human evidence; and five lactobacillus strains, for which the Cochrane review is null and the positive trials used a suppository.
And it prints two blend totals with no individual amount, so none of those ingredients can be checked against the research described on this page. That is the central limitation and it is stated on every product page here, not only in this guide.
If you want a single capsule with all of it and you accept that you cannot audit the amounts, that is a reasonable trade and the 60-day guarantee limits what it costs you to find out. If you would rather buy one ingredient with a printed dose, a standalone cranberry extract with its proanthocyanidin content on the tub is easier to check and cheaper. And if what you actually have is a bladder control problem rather than recurrent infection, please read the first table on this page again before you buy anything at all.
Every page, every journal post, the bottle facts and the ingredients go through review by Dr. Jennifer Roelands, MD before they ship. We write these pages from the printed Femipro bottle and from the Supplement Facts panel photographed in our own stock images, cite public research for cranberry, bearberry, berberine, mimosa pudica and the named lactobacillus strains, and print “not published” wherever a figure is not disclosed rather than estimating it. This label publishes two blend totals and no individual amount, and that fact appears on every page where an ingredient is named. Where the seller’s marketing claims more than the bottle supports, we say so on the page. Corrections are made on the page itself and the review date moves forward. Write to [email protected]. Last reviewed September 2026 by Dr. Jennifer Roelands, MD.
Sources for this guide
- Cochrane review, pelvic floor muscle training, 2018. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews. 2018;10:CD005654. View source
- American College of Physicians guideline, 2014. Qaseem A, Dallas P, Forciea MA, et al. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. 2014;161(6):429-440. View source
- Cochrane review, cranberry and UTI, 2023. Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews. 2023;11(11):CD001321. View source
- Fu, meta-analysis in healthy women, 2017. Fu Z, Liska D, Talan D, Chung M. Cranberry reduces the risk of urinary tract infection recurrence in otherwise healthy women: a systematic review and meta-analysis. Journal of Nutrition. 2017;147(12):2282-2288. View source
- Howell, proanthocyanidin dose and anti-adhesion, 2010. Howell AB, Botto H, Combescure C, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content. BMC Infectious Diseases. 2010;10:94. View source
- NCCIH, cranberry usefulness and safety. National Center for Complementary and Integrative Health. Cranberry: Usefulness and Safety. National Institutes of Health. View source
- Cochrane review, probiotics and UTI, 2015. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database of Systematic Reviews. 2015;(12):CD008772. View source
- Stapleton, L. crispatus for recurrent UTI, 2011. Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clinical Infectious Diseases. 2011;52(10):1212-1217. View source
- Cohen, L. crispatus and bacterial vaginosis, 2020. Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. New England Journal of Medicine. 2020;382(20):1906-1915. View source
- Abdullatif, probiotics in premenopausal women, 2021. Abdullatif VA, Sur RL, Eshaghian E, et al. Efficacy of probiotics as prophylaxis for urinary tract infections in premenopausal women: a systematic review and meta-analysis. Cureus. 2021;13(10):e18843. Published in a journal with minimal peer review. View source
- Ravel, the vaginal microbiome, 2011. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences. 2011;108(Suppl 1):4680-4687. View source
- NCCIH, probiotics usefulness and safety. National Center for Complementary and Integrative Health. Probiotics: Usefulness and Safety. National Institutes of Health. View source
- REGATTA trial, uva-ursi versus fosfomycin, 2021. Gagyor I, Hummers E, Schmiemann G, et al. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clinical Microbiology and Infection. 2021;27(10):1441-1447. View source
- ATAFUTI trial, uva-ursi and ibuprofen, 2019. Moore M, Trill J, Simpson C, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 2019;25(8):973-980. View source
- Schindler, arbutin excreted as hydroquinone, 2002. Schindler G, Patzak U, Brinkhaus B, et al. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. Journal of Clinical Pharmacology. 2002;42(8):920-927. View source
- de Arriba, hydroquinone risk assessment, 2013. de Arriba SG, Naser B, Nolte KU. Risk assessment of free hydroquinone derived from Arctostaphylos uva-ursi folium herbal preparations. International Journal of Toxicology. 2013;32(6):442-453. All three authors were employed by a bearberry product manufacturer. View source
- Khoshandam, berberine pharmacokinetics, 2022. Khoshandam A, Imenshahidi M, Hosseinzadeh H. Pharmacokinetic of berberine, the main constituent of Berberis vulgaris L.: a comprehensive review. Phytotherapy Research. 2022;36(11):4063-4079. View source
- Blais, berberine meta-analysis, 2023. Blais JE, Huang X, Zhao JV. Overall and sex-specific effect of berberine for the treatment of dyslipidemia in adults: a systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2023;83(5):403-427. View source
- Xin, berberine raises ciclosporin levels, 2006. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods and Findings in Experimental and Clinical Pharmacology. 2006;28(1):25-29. View source
- Nguyen, goldenseal and metformin crossover trial, 2025. Nguyen JT, Tian DD, Kellogg JJ, et al. The pharmacokinetic interaction between metformin and the natural product goldenseal is metformin dose-dependent: a three-arm crossover study in adults with type 2 diabetes. Clinical and Translational Science. 2025;18(2):e70120. The botanical tested was goldenseal, a berberine-containing plant, not isolated berberine hydrochloride. View source
- Robinson, Jamaican plant extracts in vitro, 1990. Robinson RD, Williams LA, Lindo JF, Terry SI, Mansingh A. Inactivation of Strongyloides stercoralis filariform larvae in vitro by six Jamaican plant extracts and three commercial anthelmintics. West Indian Medical Journal. 1990;39(4):213-217. Leaf material in a petri dish, not seed extract in a person. View source
- Nghonjuyi, Mimosa pudica in infected chicks, 2020. Nghonjuyi NW, Tiambo CK, Kimbi HK, et al. Mimosa pudica and Carica papaya extracts on Ascaridia galli: experimentally infected Kabir chicks in Cameroon. Veterinary Parasitology: Regional Studies and Reports. 2020;19:100354. A poultry study. View source
- Noor, Mimosa pudica seed mucilage, 2024. Noor M, Muhammad G, Hanif H, et al. Structure, chemical modification, and functional applications of mucilage from Mimosa pudica seeds: a review. International Journal of Biological Macromolecules. 2024;270(Pt 2):132390. Materials chemistry, with no human health outcome of any kind. View source
- NOBLE study, overactive bladder in the US, 2003. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World Journal of Urology. 2003;20(6):327-336. View source
- MedlinePlus, urinary incontinence. MedlinePlus. Urinary Incontinence. National Library of Medicine, National Institutes of Health. View source
- NIDDK, bladder control problems in women. National Institute of Diabetes and Digestive and Kidney Diseases. Bladder Control Problems (Urinary Incontinence). National Institutes of Health. View source
- FDA, mixing medicines and supplements. U.S. Food and Drug Administration. Mixing Medications and Dietary Supplements Can Endanger Your Health. View source
- FDA, dietary supplements. U.S. Food and Drug Administration. Dietary Supplements. The agency's hub for how supplements are regulated under DSHEA, including what is and is not reviewed before a product reaches the market. View source
- NIH Office of Dietary Supplements, what you need to know. National Institutes of Health, Office of Dietary Supplements. Dietary Supplements: What You Need to Know. Explains what a supplement is, what a label must carry, and that supplements are not reviewed for safety or effectiveness before they are sold. View source
- FTC health products compliance guidance. Federal Trade Commission. Health Products Compliance Guidance. Requires competent and reliable scientific evidence for health claims, and states that consumer testimonials cannot substitute for it. View source